Market Overview:
The global postmenopausal osteoporosis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of osteoporosis, rising geriatric population, and growing awareness about available treatment options. Based on type, the bisphosphonates segment is expected to account for the largest share of the global postmenopausal osteoporosis therapeutics market in 2018. This segment is also projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to factors such as increasing incidence of bone fractures and rising demand for effective and safe treatments for osteoporosis. Based on application, hospital pharmacies are expected to account for the largest share of the global postmenopausal osteoporosis therapeutics market in 2018.
Product Definition:
Postmenopausal osteoporosis is a disease that affects women after menopause and is characterized by a decrease in bone mass. This leads to an increased risk of fractures, especially in the spine, hips, and wrists. Treatment for postmenopausal osteoporosis includes medications that increase bone density such as bisphosphonates and denosumab as well as lifestyle changes such as exercise and diet modifications.
Bisphosphonates:
Bisphosphonates are a group of chemical compounds that act as bone strengtheners. They work by increasing the strength of bones to resist breakage and fractures. The most commonly used drugs are Alendronate (Fosamax), Erythropoietin (Epogen), and Amodipinoic Acid (Amodia).
Hormones:
Osteoporosis is a disease characterized by reduced bone mass and porous bones that causes severe fractures if not treated. Osteoporosis affects millions of people globally, especially women after menopause. The disease has become more common owing to the growing geriatric population and sedentary lifestyles of individuals across the globe.
Application Insights:
The postmenopausal osteoporosis therapies market is categorized based on the application into hospital pharmacies, online pharmacies and retail pharmacies. The hospital pharmacy segment dominated the market in 2017 due to high usage of bisphosphonates for treatment of osteoporosis in this setting. In addition, an increasing number of healthcare facilities along with rising geriatric population is expected to contribute towards revenue growth over the forecast period.
The online pharmacy segment is anticipated to witness lucrative growth over the forecast period owing to easy availability and affordability of these medicines compared to other alternative treatments available in the market at present time. In addition, growing awareness about various benefits associated with home healthcare management such as convenience and ease along with tracking ability may further boost demand for online prescriptions which will subsequently propel industry growth during future years.
Regional Analysis:
North America dominated the global postmenopausal osteoporosis therapeutics market in 2017. This is attributed to the high prevalence of osteoporosis-related fractures, increasing geriatric population, and rising healthcare expenditure in this region. Moreover, government initiatives for improving healthcare infrastructure are expected to drive growth during the forecast period. For instance, as part of its efforts to make medical assistance more accessible & affordable (MAA), Medicare Part B covers around 80% of medically necessary prescription drug costs for patients with incomes up to 000 annually and 25% off list price if prescribed by a doctor at an in-network pharmacy.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improved economic conditions resulting from rapid industrialization & urbanization processes across countries such as China & India.
Growth Factors:
- Increasing incidence of postmenopausal osteoporosis
- Growing geriatric population
- Rising awareness about postmenopausal osteoporosis and its treatment options
- Availability of novel therapeutics for the treatment of postmenopausal osteoporosis
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Postmenopausal Osteoporosis Therapeutics Market Research Report
By Type
Bisphosphonates, Hormones, Strontium Ranelate, Raloxifene, Denosumab, Others
By Application
Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
By Companies
Eli Lilly, Pfizer, F. Hoffman La Roche, Procter & Gamble, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Postmenopausal Osteoporosis Therapeutics Market Report Segments:
The global Postmenopausal Osteoporosis Therapeutics market is segmented on the basis of:
Types
Bisphosphonates, Hormones, Strontium Ranelate, Raloxifene, Denosumab, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Pfizer
- F. Hoffman La Roche
- Procter & Gamble
- Merck
Highlights of The Postmenopausal Osteoporosis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bisphosphonates
- Hormones
- Strontium Ranelate
- Raloxifene
- Denosumab
- Others
- By Application:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Postmenopausal Osteoporosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Postmenopausal osteoporosis therapeutics are medications used to treat postmenopausal women who have low bone density. These medications can help to improve the strength and density of bones in the body.
Some of the major players in the postmenopausal osteoporosis therapeutics market are Eli Lilly, Pfizer, F. Hoffman La Roche, Procter & Gamble, Merck.
The postmenopausal osteoporosis therapeutics market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Postmenopausal Osteoporosis Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Postmenopausal Osteoporosis Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Postmenopausal Osteoporosis Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Postmenopausal Osteoporosis Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Postmenopausal Osteoporosis Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Postmenopausal Osteoporosis Therapeutics Market Size and Y-o-Y Growth
4.5.2 Postmenopausal Osteoporosis Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Bisphosphonates
5.2.2 Hormones
5.2.3 Strontium Ranelate
5.2.4 Raloxifene
5.2.5 Denosumab
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Online Pharmacies
6.2.3 Retail Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Postmenopausal Osteoporosis Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Postmenopausal Osteoporosis Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Bisphosphonates
9.6.2 Hormones
9.6.3 Strontium Ranelate
9.6.4 Raloxifene
9.6.5 Denosumab
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Online Pharmacies
9.10.3 Retail Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Bisphosphonates
10.6.2 Hormones
10.6.3 Strontium Ranelate
10.6.4 Raloxifene
10.6.5 Denosumab
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Online Pharmacies
10.10.3 Retail Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Bisphosphonates
11.6.2 Hormones
11.6.3 Strontium Ranelate
11.6.4 Raloxifene
11.6.5 Denosumab
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Online Pharmacies
11.10.3 Retail Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Bisphosphonates
12.6.2 Hormones
12.6.3 Strontium Ranelate
12.6.4 Raloxifene
12.6.5 Denosumab
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Online Pharmacies
12.10.3 Retail Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Bisphosphonates
13.6.2 Hormones
13.6.3 Strontium Ranelate
13.6.4 Raloxifene
13.6.5 Denosumab
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Online Pharmacies
13.10.3 Retail Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Postmenopausal Osteoporosis Therapeutics Market: Competitive Dashboard
14.2 Global Postmenopausal Osteoporosis Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly
14.3.2 Pfizer
14.3.3 F. Hoffman La Roche
14.3.4 Procter & Gamble
14.3.5 Merck
